Statistics for Y-mAbs Therapeutics (id:8187 YMAB)

Valuation metrics

Market cap

519.11M

Enterprise value

523.27M

Trailing P/E (ttm)

-21.24

Forward P/E

-19.98

PEG ratio

-19.98

Price/Sales (ttm)

6.14

Price/Book (mrq)

5.61

Enterprise Value/Revenue

6.19

Enterprise Value/EBITDA

-22.41

Overview

Shares outstanding

44.79M

Float

27.29M

Shares short

4.01M

% Held by insiders

0.12%

% Held by institutions

0.69%

Average volume (10 days)

346.67K

Average volume (90 days)

Price summary

52-Week low

5.31

52-Week high

20.90

52-Week change

46.78%

Beta

0.67

50-Day moving average

14.08

200-Day moving average

13.83

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

-28.22%

Operating margin

-42.52%

Operational effectiveness

Return on assets

-11.98%

Return on equity

-24.78%

Income statement

Revenue (ttm)

1.92

Revenue per share (ttm)

1.92

Quarterly revenue growth (yoy)

Gross profit (ttm)

73.40M

EBITDA

-23,352,000.00

Net income to common (ttm)

-23,864,000.00

Diluted EPS (ttm)

-0.54

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

68.12M

Total cash per share (mrq)

1.52

Total debt (mrq)

1.08M

Total Debt/Equity (mrq)

1.16

Current ratio (mrq)

391.70%

Book value per share (mrq)

2.06

Cash flow

Cash flow statement

-21,880,000.00

Levered free cash flow (LFCF)

1.19M